Belarus vs Denmark: Statin use vs. average non-HDL cholesterol levels
Belarus
3.2
in 2018
Denmark
3.2
in 2018
Belarus rank
118th
Denmark rank
118th
Statin use vs. average non-HDL cholesterol levels over time
- Belarus
- Denmark
How they compare
Belarus currently reports 3.2 against 3.2 in Denmark, a difference of 0.
The two have swapped places 4 times across 39 shared years of data; in 1980 it was Denmark ahead.
Belarus ranks 118th and Denmark ranks 118th of 191 countries.
Across the 4 decades both report, Belarus averaged higher in 1 and Denmark in 3.
Head to head by decade
| Decade | Belarus | Denmark | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 4 | 4.39 | 0.39 | Denmark |
| 1990s | 3.92 | 4.2 | 0.28 | Denmark |
| 2000s | 3.69 | 3.78 | 0.09 | Denmark |
| 2010s | 3.39 | 3.38 | 0.0111 | Belarus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Belarus or Denmark?
- Belarus, at 3.2 against 3.2 in Denmark as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Belarus and Denmark?
- 0, with Belarus ahead.
- How many years of comparable data are there for Belarus and Denmark?
- 39 years are reported by both, from 1980 to 2018.
- How do Belarus and Denmark rank globally for statin use vs. average non-hdl cholesterol levels?
- Belarus ranks 118th and Denmark ranks 118th of 191 countries.
- Where does this data come from?
- World Health Organization – Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.